Opaleye Management’s TG Therapeutics TGTX Stock Holding History

Opaleye Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29.4M	Hold	535,000	–	–	2.66%	10
2026 Q1	$17.8M	Hold	535,000	–	–	2.34%	14
2025 Q4	$15.9M	Hold	535,000	–	–	2.1%	11
2025 Q3	$19.3M	Hold	535,000	–	–	2.73%	8
2025 Q2	$19.3M	Hold	535,000	–	–	3.9%	8
2025 Q1	$21.1M	Sell	535,000 -1,725,000	-76%	-$58M	4.7%	8
2024 Q4	$68M	Sell	2,260,000 -20,000	-0.9%	-$574K	11.9%	2
2024 Q3	$53.3M	Hold	2,280,000	–	–	8.89%	2
2024 Q2	$40.6M	Hold	2,280,000	–	–	9.27%	2
2024 Q1	$34.7M	Buy	2,280,000 +65,000	+3%	+$1.04M	7.56%	3
2023 Q4	$37.8M	Buy	2,215,000 +325,000	+17%	+$3.78M	10.06%	2
2023 Q3	$15.8M	Buy	+1,890,000	New	+$26.3M	5.14%	4
2021 Q1	–	Sell	-387,500	Closed	-$20.2M	–	66
2020 Q4	$20.2M	Sell	387,500 -2,500	-0.6%	-$84.5K	2.63%	11
2020 Q3	$10.4M	Sell	390,000 -66,600	-15%	-$1.53M	2.04%	18
2020 Q2	$8.89M	Sell	456,600 -36,400	-7%	-$586K	1.8%	18
2020 Q1	$4.85M	Sell	493,000 -86,651	-15%	-$1.09M	1.29%	25
2019 Q4	$6.43M	Sell	579,651 -32,849	-5%	-$250K	1.26%	35
2019 Q3	$3.44M	Sell	612,500 -537,500	-47%	-$3.75M	1.24%	30
2019 Q2	$9.95M	Sell	1,150,000 -216,062	-16%	-$1.63M	3.03%	14
2019 Q1	$11M	Buy	1,366,062 +816,062	+148%	+$4.41M	3.04%	8
2018 Q4	$2.25M	Buy	550,000 +200,000	+57%	+$994K	0.84%	32
2018 Q3	$1.96M	Sell	350,000 -275,000	-44%	-$3.14M	0.5%	38
2018 Q2	$8.22M	Buy	625,000 +350,800	+128%	+$4.82M	2.13%	13
2018 Q1	$3.89M	Buy	+274,200	New	+$3.5M	1.11%	28
2016 Q3	–	Sell	-175,000	Closed	-$1.06M	–	51
2016 Q2	$1.06M	Sell	175,000 -240,000	-58%	-$1.95M	0.71%	44
2016 Q1	$3.54M	Buy	415,000 +115,000	+38%	+$1.01M	2.21%	20
2015 Q4	$3.58M	Buy	300,000 +40,000	+15%	+$505K	1.5%	29
2015 Q3	$2.62M	Buy	+260,000	New	+$3.87M	1.29%	32

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Opaleye Management's TGTX Position: Q2 2026 in Review

Opaleye Management held its TG Therapeutics (TGTX) position steady in Q2 2026 at 535,000 shares worth $29.4M. The position accounts for 2.66% of the portfolio, ranked #10.

Opaleye Management first reported a position in TGTX in Q3 2015 and has held it in 28 quarters since. The position peaked at $68M in Q4 2024. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Opaleye Management held 535,000 shares of TG Therapeutics worth $29.4M as of Q2 2026.
Opaleye Management left its TG Therapeutics share count unchanged in Q2 2026.
TG Therapeutics made up 2.66% of Opaleye Management's portfolio in Q2 2026, its #10 holding.
Opaleye Management first reported a position in TG Therapeutics in Q3 2015 and has held it in 28 quarters since.
Opaleye Management's TG Therapeutics position peaked at $68M in Q4 2024.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.